title: [Effects of imatinib mesylate on the levels of endocrine hormones].
abstract: OBJECTIVE
  To measure the levels of hormones in chronic myelogenous leukemia (CML) patients receiving imatinib mesylate (IM) and evaluate the effects of IM on endocrine system.
  
  
  METHODS
  69 patients with CML while taking IM were enrolled and a total of 86 peripheral blood samples were detected. The levels of total triiodothyronine (TT3), total tetraiodothyronine (TT4), thyroid stimulating hormone (TSH), testosterone, progesterone, estradiol (E2), plasma total cortisol (PTC) at 8:00-10:00 am measured. Concentration of hormones in different groups were measured to evaluate the effects of IM on endocrine system and relationships with its administration duration, plasma concentration and clinical symptoms.
  
  
  RESULTS
  (1) Of the 7 types of hormones, an elevation of TSH level was found in 14 patients (20.3%), a decrease of TT3 and testosterone in 8 patients (11.6%) and 8 males (18.6%), respectively. (2) A significant decline of TT3 and testosterone was observed in all patients divided by different administration duration. Negative correlation was seen between TT3 level and duration of administration (r=-0.273, P=0.010), which was also found for testosterone (r=-0.302, P=0.025). (3) There was no correlation between serum levels of the seven hormones and concentration of IM.
  
  
  CONCLUSIONS
  IM affect the levels of thyroid and sex hormones in some patients with clinical manifestations: a decrease of TT3, testosterone and testosterone, an increase of TSH, which have relationship with the duration of administration.
authors.affiliation: Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Hou
authors.forename: Huan-ling
authors.initials: HL
authors.lastname: Zhu
authors.forename: Ting
authors.initials: T
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood*; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D014284:Triiodothyronine; D000068877:Imatinib Mesylate; D013972:Thyrotropin